Entrectinib standard dosage instructions for adults and children

The dose setting of Entrectinib for the treatment of non-small cell lung cancer or solid tumors is determined based on the patient's age, weight and specific indications. There are certain differences in the usage standards between children and adults. For adults and adolescents weighing 40 kg or more, the recommended standard oral dose is 600 mg once a day, continuously. The drug can be taken with food or on an empty stomach, but it is recommended to take it at the same time every day to maintain stable blood concentration. This dose is the standard regimen used in most clinical trials and ensures effective levels of TRK, ROS1 and ALK inhibition in vivo while taking into account tolerability.

In terms of medication for children, the dosage needs to be adjusted individually based on the body surface area (BSA). Body surface area (BSA) greater than 1.5m2: 600mg orally once a day; BSA 1.11-1.5m2: 500mg orally once a day; BSA 0.91-1.1 m2: 400mg orally once a day. Since the pharmacokinetic characteristics of children are different from those of adults, adverse reactions such as weight gain, abnormal liver function, and prolongation of the QT interval on electrocardiogram need to be monitored more closely during the use of entrectinib. Doctors need to dynamically assess the drug response and adjust the dose, temporarily stop the drug, or reduce the dose when necessary.

It should be noted that throughout the entire treatment cycle, patients must undergo regular blood tests, liver and kidney function monitoring, and imaging evaluations to ensure efficacy and medication safety. For patients who experience obvious adverse reactions, such as neurological symptoms, cardiotoxicity, etc., they must communicate with the attending doctor in a timely manner and are not allowed to stop taking the medicine without authorization or increase or decrease the dose on their own. In addition, entrectinib is an oral preparation and must be swallowed whole. Do not chew or break it to avoid affecting drug release and bioavailability. In pediatric patients with dysphagia, physicians may evaluate whether a modified medication or liquid regimen may be an alternative, but this will need to be done in accordance with formal guidelines.

Reference materials:https://www.roche.com/products/rozlytrek